Ligand id: 6771

Name: bevacizumab

No information available.
Summary of Clinical Use
Used as part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer. In August 2014 the US FDA granted additional approval for metastatic cervical cancer. In November 2014, FDA approval was extended to include a combination therapy of bevacizumab plus chemotherapy (paclitaxel, pegylated liposomal doxorubicin or topotecan) for platinum-resistant, recurrent ovarian cancer (based on findings from the Phase 3 AURELIA clinical trial NCT00976911). Additional Phase 2 clinical trial results are provided in [5]. In June 2018, FDA approval was further expanded to include the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, in patients with stage III or IV disease, and to be used after initial surgical resection [2] [4].
Clinical trials evaluating bevacizumab in combination with the immune checkpoint inhibitors ipilimumab (anti-CTLA4) or nivolumab (anti-PD-1) in advanced solid malignancies are underway (for example NCT01950390- Phase 2 stage III-IV melanoma; NCT01454102- Phase 1 stage IIIB/IV non-small cell lung cancer).

A re-engineered version of bevacizumab with a different glycosylation profile (bevacizumab beta, ABP 215) is in Phase 3 clinical trial for metastatic non-small cell lung cancers (NSCLC), This trial, NCT01966003 is comparing bevacizumab beta vs. the original bevacizumab,
Mechanism Of Action and Pharmacodynamic Effects
A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) which reduces or prevents angiogenesis. The rationale behind anti-VEGF as an anti-angiogenic therapy is described in [3].
External links